Drug Transporter Gene Expression in Human Colorectal Tissue and Cell Lines: Modulation with Antiretrovirals for Microbicide Optimization

Indrani Mukhopadhya, Graeme I. Murray, Susan Berry, John Thomson, Bruce Frank, Garry Gwozdz, Julia Ekeruche-Makinde, Robin Shattock, Charles Kelly, Francesco Iannelli, Gianni Pozzi, Emad M. El-Omar, Georgina L. Hold, Karolin Hijazi

Research output: Contribution to journalArticlepeer-review

14 Citations (Scopus)
16 Downloads (Pure)


Objectives To comprehensively assess mRNA expression of 84 drug transporters in human colorectal biopsies and 6 representative cell lines. To investigate the alteration of drug transporter gene expression after exposure to three candidate microbicidal ARV drugs, (tenofovir, darunavir and dapivirine) in Caco-2 cells. The outcome of the objectives informs development of optimal antiretroviral (ARV)-based microbicidal formulations for prevention of HIV-1 infection.
Methods Drug transporter mRNA expression was quantified from colorectal biopsies and cell-lines by quantitative real-time PCR. Relative mRNA expression was quantified in Caco-2 cells after induction with ARVs. Data was analysed using Pearson’s correlation coefficients (r), hierarchical clustering and principal component analysis (PCA).
Results Expression of 58 of the 84 transporters was documented in colorectal biopsies, with CNT2, P-gp and MRP3 being the highest expressed. No difference was noted between individual subjects, when analysed by age, gender or biopsy site (rectum or recto-sigmoid) (r=0.95-0.99). High expression of P-gp and CNT2 proteins was confirmed by immunohistochemical staining. Similarity between colorectal tissue and cell-line drug transporter gene expression was variable (r = 0.64-0.84). PCA showed distinct clustering of human colorectal biopsy samples with the Caco-2 cells defined as the best surrogate system. Induction of Caco-2 cell-lines with ARV drugs suggests that darunavir-based microbicides incorporating tenofovir may result in drug-drug interactions likely to affect distribution of individual drugs to sub-epithelial target cells.
Conclusions These findings will help optimise complex formulations of rectal microbicides to realise their full potential as an effective approach for pre-exposure prophylaxis against HIV-1 infection.
Original languageEnglish
Pages (from-to)372-386
Number of pages15
JournalJournal of Antimicrobial Chemotherapy
Issue number2
Early online date29 Oct 2015
Publication statusPublished - Feb 2016

Bibliographical note

This work was supported by the European Union's Seventh Framework Programme for research, technological development and demonstration under grant agreement No 305316 as part of the MOTIF (Microbicide Optimization Through Innovative Formulation for Vaginal and Rectal Delivery) project.

We thank members of the MOTIF consortium for useful discussions and exchange of ideas during the course of this study. We would like to extend our thanks to the study participants and the clinical teams for their invaluable contribution. We thank NHS Grampian Biorepository for support in performing the immunohistochemical studies, Janssen R&D Ireland for provision of darunavir and Gilead Sciences for provision of tenofovir.


Dive into the research topics of 'Drug Transporter Gene Expression in Human Colorectal Tissue and Cell Lines: Modulation with Antiretrovirals for Microbicide Optimization'. Together they form a unique fingerprint.

Cite this